ARTES and Boehringer Ingelheim Animal Health Announce Collaboration

ARTES Biotech­nol­o­gy, spe­cial­ized in recom­bi­nant pro­tein pro­duc­tion, process and vac­cine devel­op­ment from micro­bial expres­sion sys­tems announces a col­lab­o­ra­tion with the glob­al phar­ma­ceu­ti­cal com­pa­ny Boehringer Ingel­heim Ani­mal Health.

ARTES’ expres­sion sys­tem Hansenu­la poly­mor­pha is the pre­ferred tech­nol­o­gy for afford­able mass vac­ci­na­tion and rec­om­mend­ed by the World Health Orga­ni­za­tion (WHO) for these pur­pos­es. In com­bi­na­tion with ARTESMETAVAX® plat­form, this offers a new, unique and very eco­nom­i­cal approach to low-cost mass pro­duc­tion of safe and effec­tive vac­cines required in the vet­eri­nary field.

This col­lab­o­ra­tion is anoth­er mile­stone in expand­ing our vac­cine devel­op­ment exper­tise”, Michael Pio­ntek, man­ag­ing direc­tor of ARTES stat­ed. “We are more than con­fi­dent that our tech­nol­o­gy plat­form is per­fect­ly suit­ed for the devel­op­ment of safe and cost effi­cient vac­cines that are high­ly rel­e­vant for the vet­eri­nary mar­ket.”

Part­ner­ing is a cen­tral part of our strat­e­gy. We are excit­ed about this col­lab­o­ra­tion and the oppor­tu­ni­ty to devel­op more inno­v­a­tive vac­cines for the ani­mal health mar­ket,” says Rolf-Dieter Gün­ther, Head of Glob­al Busi­ness Devel­op­ment and Licens­ing Ani­mal Health for Boehringer Ingel­heim.